Photonics Healthcare
Private Company
Total funding raised: $5M
Overview
Photonics Healthcare has pioneered the first practical clinical method for measuring oxygen availability inside active human cells using its proprietary protoporphyrin IX triplet state lifetime technique (PpIX-TSLT). Its COMET measurement system is CE-marked for skin measurements and has been validated in multiple clinical trials, demonstrating its potential to provide more relevant physiological information than traditional metrics like lactate or blood pressure. The company is initially targeting perioperative and intensive care settings in Europe, with the long-term vision of expanding to other organs and imaging applications. Its technology addresses a fundamental gap in monitoring cellular metabolism and oxygen utilization.
Technology Platform
Protoporphyrin IX Triplet State Lifetime Technique (PpIX-TSLT) for non-invasive, real-time measurement of oxygen partial pressure inside cellular mitochondria.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Photonics Healthcare is a first-mover with a unique photonics-based method for direct mitochondrial oxygen measurement. It faces indirect competition from established companies offering monitoring of surrogate markers (e.g., Edwards Lifesciences for hemodynamics, Masimo for regional oximetry). Its main competition may come from other startups developing novel tissue oxygenation sensors, but the PpIX-TSLT technique appears clinically validated and distinct.